Genocea Clinical Trial

Status Of Vaccine Research And Development Of Pediatric ...
Status of Vaccine Research and Development of Pediatric Vaccines for Streptococcus pneumoniae Prepared for WHO PD-VAC I. IPD following a large clinical trial in the United Several vaccine developers including GSK, Sanofi Pasteur, and Genocea are actively advancing pneumococcal protein ... Return Doc

GENOCEA INITIATES A PHASE 1/2a STUDY WITH ITS THERAPEUTIC ...
GENOCEA INITIATES A PHASE 1/2a STUDY WITH ITS THERAPEUTIC VACCINE CANDIDATE FOR HERPES SIMPLEX VIRUS-2 (HSV-2) This study is a double-blind, placebo-controlled dose escalation clinical trial enrolling approximately 150 ... Content Retrieval

Genocea Completes Enrollment Early In Phase 2 Dose ...
Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN -003 for Treatment of Genital Herpes In the previous Phase 1/2a clinical trial, subjects in the 30 microgram per antigen and 50 microgram of adjuvant dose group ... Content Retrieval

Company Name Location Size Industry Type About/Specilization ...
Company Name Location Size Industry Type About/Specilization Website AB SCIEX Framingham, MA late-stage clinical trial activity in cancer and prevention of Genocea is developing a new class of human vaccines based ... Access Content

INsIde ThIs Issue - FDAnews
Page 2 CliNiCal Trial maGNifier WeeKly De. 5 2013 Studies Opening a First Site in a New Country: NCT01995617 GENOCEA BIOLOGICAL 2. RECRUITING 1 90 18 YEARS 55 YEARS INFECT PNEUMONIA NCT01996228 TIANHE STEM CELL DEVICE 2. RECRUITING 1 20 6 YEARS 14 ... Read Here

Herpes Simplex Research - Wikipedia, The Free Encyclopedia
Herpes simplex research includes all medical research that attempts to prevent, treat, Genocea's Vaccine announced Phase II clinical trial results in June 2014. ... Read Article

Genocea Announces Positive Top-Line Phase 1 Results For Novel ...
Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004 - Phase 2a study to commence in the third quarter of 2014 Genocea's second clinical candidate, clinical trial results; current results may not ... Retrieve Here

Www.stifel.com
21JAN201412262991 PROSPECTUS 5,500,000 Shares Genocea Biosciences, Inc. Common Stock $12.00 per share This is the initial public offering of our common stock. We are selling 5,500 ... Access Doc

Genocea Announces Positive Durability Data From 6 -Month ...
October 7, 2015 Genocea Announces Positive Durability Data from 6 -Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN -003 ... Retrieve Here

R&D: Prophylactic Vaccines Development For EV71- Dr Joseph ...
• Phase 3 clinical trial result of EV71 Visit our Website: by Central Clinical School, Monash University 235 views. 36:25 FRONTLINE | The Vaccine War Genocea Biosciencees - World Vaccine - Duration: 20:23. ... View Video

HIGHLIGHTS ORPORATE ISSION ROPRIETARY ECHNOLOGY ORPORATE LLIANCES
HSV-2 Tx: successful pre-IND meeting to set tox package and 1st clinical trial protocol; Genocea is leading the field of T cell vaccines, which we develop using a revolutionary platform for rapid antigen discovery of antigens. ... Access Doc

The Most Influential People In Vaccines
So who are the most influential people in the vaccines clinical trial, an international collaboration that involved more than 16,000 Thai volunteers, provided the world’s first demonstration that a preventive HIV vaccine was possible. Chip Clark joined Genocea Biosciences in 2010 as ... Read Content

Prophylactic Vaccines: Mucosal And Systemic Responses- Dr ...
Prophylactic vaccines: Mucosal and systemic responses- Dr Thomas Muster · Clinical trial results HSV2 vaccine development / Dr Seth Hetherington - Genocea Biosciencees - World Vaccine - Duration: 20:23. ... View Video

Trevena Inc - Wikipedia, The Free Encyclopedia
Trevena Inc a clinical stage biopharmaceutical company, headquartered in King of Prussia, PA, and is the leader in the discovery and development of G-protein coupled receptors The Phase I first-in-human clinical trial of TRV130 is complete. ... Read Article

Human Vaccines & Immunotherapeutics: News
Www.landesbioscience.com Human Vaccines & immunotherapeutics 2279 Human Vaccines & immunotherapeutics 9:11, 2279–2282 News Agenus brain cancer vaccine improves survival in phase 2 trial The biotech company Agenus recently reported positive results from an analysis of a phase 2 trial in ... Retrieve Doc

5,454,545 Shares Common Stock - Stifel
Genocea® and the Genocea logo are our registered trademarks. the uncertainty of clinical trial results and the fact that current results may not be predictive of future results, even if the data from preclinical studies or clinical trials is positive; ... Doc Retrieval

Genocea Biosciences
Genocea Biosciences Jessica Flechtner; Email: Genocea has demonstrated preclinical proof-of-concept with vac- HSV-2 therapeutic vaccine program, and clinical trial work begun on our prophylactic pneumococcal, chlamydia, ... Return Document

THERAPEUTIC HSV-2 VACCINE (GEN-003 ... - Genocea Biosciences
Conflict of interest • Genocea Biosciences, the developer of GEN-003, provided funding for the trial • PI at University of Washington for clinical trials with ... Retrieve Full Source

Genocea Commences Dosing In Phase 2b Study For Genital Herpes Treatment, GEN-003
-Top-line viral shedding data expected in mid-2016-- Six month clinical efficacy data against potential Phase 3 endpoints expected in 2 H 2016-. CAMBRIDGE, Mass., Jan. 29, 2016-- Genocea Biosciences, Inc., ... Read News

Herpes Simplex Virus Treatment: Market Research Report
BioVex Begins Phase I Clinical Trial for Immuno VEXHSV2 Genocea In-Licenses HSV Patent Estate from University of Washington Herpes Simplex Virus Treatment: Market Research Report 7. ... Fetch Content

Vtesse PR Draft FINAL FOR APPROVAL V2 - Cydanco.com
Invitrogen/BioReliance, Baxter Healthcare and Genocea Biosciences, other key stakeholders to start a Phase II/III clinical trial to assess the efficacy of the Vtesse PR draft_FINAL FOR APPROVAL v2.docx ... View Document